GSE182150 KIT LSD1 MYC inhibition 2 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE182150_KIT_LSD1_MYC inhibition_2_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE182150_KIT_LSD1_MYC inhibition_2_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE182150_KIT_LSD1_MYC inhibition_2_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE182150_KIT_LSD1_MYC inhibition_2_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

carbonic anhydrase 2

Gene

C-X-C motif chemokine ligand 8

Gene

GNAS complex locus

Gene

secretory leukocyte peptidase inhibitor

Gene

argininosuccinate synthase 1

Gene

eukaryotic translation initiation factor 5A

Gene

cell division cycle 20

Gene

serpin family A member 1

Gene

insulin like growth factor binding protein 2

Gene

solute carrier family 38 member 1

  • Gene

    carbonic anhydrase 2


  • Gene

    C-X-C motif chemokine ligand 8


  • Gene

    GNAS complex locus


  • Gene

    secretory leukocyte peptidase inhibitor


  • Gene

    argininosuccinate synthase 1


  • Gene

    eukaryotic translation initiation factor 5A


  • Gene

    cell division cycle 20


  • Gene

    serpin family A member 1


  • Gene

    insulin like growth factor binding protein 2


  • Gene

    solute carrier family 38 member 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.